ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
ALNYLAM PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$233.29+1.46 (+0.63%)
Close on Oct 19, 2026
- Market cap
- $32.26B
- P/E (TTM)
- 43.4
- Dividend yield
- –
ALNYLAM PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product revenues | $4.05B | $3.55B | $2.99B | $2.44B | $2.01B | $1.75B | $1.65B | $1.54B | $1.43B | $1.33B | $1.24B | $1.16B | 84.4% | +101.5% |
| Total TTR | $3.52B | $3.04B | $2.49B | $1.97B | $1.56B | $1.32B | $1.22B | – | – | – | – | – | 73.3% | +126.5% |
| AMVUTTRA | $3.41B | $2.89B | $2.31B | $1.77B | $1.35B | $1.09B | $970.45M | $859.19M | $749.28M | $651.31M | $557.84M | $451.15M | 71.1% | +153.4% |
| Total Rare | $530.75M | $516.58M | $499.92M | $471.70M | $456.26M | $431.27M | $422.92M | – | – | – | – | – | 11.0% | +16.3% |
| Collaborations | $521.93M | $536.26M | $553.37M | $619.37M | $325.02M | $490.86M | $510.22M | $479.68M | $849.77M | $628.27M | $546.19M | $540.42M | 10.9% | +60.6% |
| GIVLAARI | $324.83M | $315.91M | $308.49M | $286.34M | $283.51M | $264.78M | $255.87M | $250.52M | $233.63M | $229.40M | $219.25M | $207.01M | 6.8% | +14.6% |
| Royalty revenue | $228.22M | $196.53M | $174.02M | $148.04M | $125.22M | $107.64M | $91.79M | $73.43M | $59.95M | $44.76M | $40.63M | $26.33M | 4.8% | +82.3% |
| OXLUMO | $205.92M | $200.67M | $191.44M | $185.36M | $172.75M | $166.49M | $167.05M | $156.21M | $144.72M | $128.33M | $109.84M | $100.94M | 4.3% | +19.2% |
| ONPATTRO | $109.70M | $143.78M | $172.79M | $197.21M | $208.42M | $233.13M | $252.86M | $275.76M | $307.06M | $321.27M | $354.55M | $397.76M | 2.3% | -47.4% |
By region
From the segment and revenue-disaggregation notes of Alnylam Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.